Status:
TERMINATED
Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Post Traumatic Stress Disorder
Eligibility:
All Genders
18-89 years
Phase:
PHASE2
Brief Summary
A Double-Blind Placebo-Controlled Random Order Crossover Pilot Study of Iloperidone for Symptoms of Arousal in PTSD.
Detailed Description
During Period A, subjects will receive 8 weeks of iloperidone or placebo (2 weeks titration period followed by 6 weeks on stable dose). Then they will be reassessed for response during Period A; study...
Eligibility Criteria
Inclusion
- PTSD diagnosis
Exclusion
- Pregnancy
- Traumatic Brain Injury greater than mild
- Primary sleep disorder
- Caffeinism
- Active substance use disorder
- Active suicidal risk
- Antipsychotic medication, antibiotics, sedatives, some antihypertensive or antiarrhythmic medication
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01917318
Start Date
July 1 2013
End Date
February 1 2014
Last Update
February 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Depression Center; Clinical and Translational Research Center (CTRC)
Aurora, Colorado, United States, 80045